MANREMYC
MANREMYC is a “spin off” of the Institut for Biomedical Research Germans Trias i Pujol (IGTP) with the mission to eradicate tuberculosis (TB) by reducing its risk of development with a unique and revolutionary product, Nyaditum resae® (NR) based on the most updated technology and a solid scientific background.
MANREMYC
Industry:
Biotechnology Information Technology
Founded:
2013-01-01
Address:
Manresa, Catalonia, Spain
Country:
Spain
Website Url:
http://www.manremyc.cat
Total Employee:
1+
Status:
Active
Total Funding:
98.91 K EUR
Technology used in webpage:
Viewport Meta IPhone / Mobile Compatible SPF SSL By Default LetsEncrypt Domain Not Resolving Mobile Non Scaleable Content Nginx Google Maps Parallels Plesk Panel
Current Advisors List
Current Employees Featured
Founder
Official Site Inspections
http://www.manremyc.cat
- Host name: ip125.ip-178-33-164.eu
- IP address: 178.33.164.125
- Location: Madrid Spain
- Latitude: 40.4143
- Longitude: -3.7016
- Timezone: Europe/Madrid
- Postal: 28008
More informations about "Manremyc"
Manremic – Health first - manremyc.cat
Manremyc brings you back to nature thanks to bacteria that multiply in the meadows of the high mountains, where there is a flora that is generated from the water originating from the melting …See details»
About us – Manremic - manremyc.cat
What is Manremyc? It was founded in 2013 by the physician and microbiologist Dr. Pere-Joan Cardona, researcher and specialist in mycobacteria, who acts as scientific advisor to the …See details»
Arxius - manremyc.cat
MANREMYC is a “spin off” of the Institut for Biomedical Research Germans Trias i Pujol (IGTP) with the mission to develop the benefits of inactivated M. manresensisSee details»
Manremyc - Crunchbase Company Profile & Funding
MANREMYC is a “spin off” of the Institut for Biomedical Research Germans Trias i Pujol (IGTP) with the mission to eradicate tuberculosis (TB) by reducing its risk of development with a …See details»
Manremyc Company Profile 2024: Valuation, Funding & Investors
Developer of drugs and vaccines designed to eradicate tuberculosis by reducing its risk of development. The company's drug and vaccine offers Nyaditum resale that contains an …See details»
MANREMYC, S.L. | Manresa, Spain Startup - gust.com
MANREMYC is a “spin off” of the IGTP, devoted to the development of Nyaditum resae®, a natural probiotic technology. We are a SME, leaded by DR Pere-Joan Cardona. Our BM is …See details»
MANREMYC, S.L. - LinkedIn
MANREMYC, S.L. | 209 followers on LinkedIn. Exploring the benefits of inactivated M. manresensis. | MANREMYC is a “spin off” of the Institut for Biomedical Research Germans …See details»
Manresana de Micobacteriologia, s.l. | NW Manresa Ct, Portland
MANREMYC® is a company devoted to the development of Nyaditum resae®, a natural probiotic able to protect against active tuberculosis. Find investment information and connect with …See details»
MANREMYC Company Profile - Office Locations, Competitors
See insights on MANREMYC including office locations, competitors, revenue, financials, executives, subsidiaries and more at Craft.See details»
Manremyc - Company Profile - Tracxn
Nov 17, 2024 · Manremyc - Nutraceutical probiotic product as a prophylactic against Tuberculosis. Founded by Pere-Joan Cardona, Cristina Vilaplana and 2 others in the year …See details»
Manremyc, galardonada como mejor nueva empresa por la
Manremyc, spin-off biotecnológica del Instituto Germans Trias dirigida por el investigador CIBERES Pere-Joan Cardona, ha sido galardonada en los Reconocimientos CECOT 2015 al …See details»
Manremyc - Products, Competitors, Financials, Employees, …
Manremyc is a biotechnology company focused on developing the benefits of inactivated M. Use the CB Insights Platform to explore Manremyc's full profile.See details»
Manremyc - Contacts, Employees, Board Members, Advisors
Manremyc has 3 current employee profiles, including Co-founder & CEO Pere-Joan Cardona. Manremyc has 1 board member or advisor, Jaume Amat Riera.See details»
Manremyc wins the B-Corp Certification - LinkedIn
Apr 22, 2016 · We are very proud to communicate that Manremyc has won the B-corp certification because the high social impact of the product that is developing (the Nyaditum resae), the first …See details»
Manremyc in COVID19 - Clinical Trials Registry - ICH GCP
Jun 25, 2020 · The purpose of this study is to assess the efficacy of Manremyc® food supplement for reduce the incidence of SARS-CoV-2 infection in a high risk population, as healthcare …See details»
Qui som – Manremic - manremyc.cat
Què és Manremyc? Va ser fundada el 2013 pel metge i microbiòleg Dr. Pere-Joan Cardona, investigador i especialista en micobacteris, que fa d’assessor científic de la companyia. …See details»
Manremyc - CB Insights
Jul 31, 2019 · See Manremyc funding rounds, investors, investments, exits and more. Evaluate their financials based on Manremyc's post-money valuation and revenue.See details»
Contact – Manremic - manremyc.cat
Leave us your details and the reason for your query and we will get back to you as soon as we can.See details»
Transforming Communities for Cats | Alley Cat Allies
Oct 29, 2024 · Get the latest cat news, information, and ways to take action and save cats’ lives! Since 1990, Alley Cat Allies has led the movement to protect and improve the lives of ALL …See details»
Compromís – Manremic - manremyc.cat
Les Empreses B Corp representen el model d’empresa sostenible i regenerativa més avançat del món. Manremyc, com B Corp, compleix els alts estàndards d’acompliment social i ambiental, …See details»